Therefore, the use of specific chemical mimetics of BH3 only proteins—which were developed to inhibit the anti‐apoptotic effect of BCL‐2 family members and induce cell death—constitutes a logical strategy to treat EBV‐positive lymphoproliferative disorders. This evidence concerns the gene BCL2 and lymphoproliferative syndrome.